Smoking status: not checked. AREDS2 Formula: what these mean for you changes depending on whether you smoke or used to, and you have not told us. That check was skipped.

AREDS2 Formula vs Dulaglutide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

AREDS2 Formula vs Dulaglutide: they're closely matched on evidence (7 vs 7/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Too Close to Call

AREDS2 Formula and Dulaglutide are closely matched across evidence, studies, and safety.

AREDS2 Formula1 win

Dulaglutide1 win

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Ar27.0

AREDS2 Formula

Too few graded studiesModerate safety

Dul7.0

Dulaglutide

Too few graded studiesLimited safety

Evidence

Evidence Score

Tie7/10

Studies: 39

Meta-analyses: 2

Level: Strong

Evidence Score

Tie7/10

Studies: 143

Meta-analyses: 15

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Vision & eye healthToo few graded studies33
Micronutrient & trace-element statusMostly mechanism / observational3
Cognitive functionToo few graded studies2

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies106
Weight managementToo few graded studies18
Cardiovascular outcomesToo few graded studies18

Dosage & timing

Recommended Dosage:

One AREDS2 daily regimen, usually split into two servings: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg (as zinc oxide) and copper 2 mg (as cupric oxide)

Warnings

Do not use the original beta-carotene AREDS formula if you smoke or have ever smoked — this is the single most safety-relevant fact about the product
Zinc and genitourinary problems: in the original AREDS trial, zinc was associated with a higher rate of genitourinary problems in MEN — the majority of the population taking this formula. AREDS2 found no difference between its high- and low-dose zinc groups. Gastrointestinal symptoms were the main reported adverse effect overall.
This formula does NOT prevent age-related macular degeneration in people who do not have it; Cochrane rates that as high-certainty for the individual antioxidants it tested — this formula was never trialled for prevention
It does not restore lost vision — every measured outcome was slower progression, never recovery
The evidence applies to intermediate AMD, or advanced AMD in one eye. People with only small drusen had a 1.3% five-year progression risk and gained nothing
80 mg of zinc is above established upper intake levels; the 2 mg of copper is there to prevent zinc-induced copper deficiency and must not be omitted
Adding omega-3 is not evidence-based — DHA+EPA was tested in AREDS2 and was null at both 5 and 10 years
Adding lutein/zeaxanthin did not, in the primary analysis, improve on the original formula; its established value is as a safe replacement for beta-carotene

Best Time:

With meals

Take with food

Best Form:

A product matching the AREDS2 composition exactly: vitamin C 500 mg, vitamin E 400 IU, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg

Recommended Dosage:

Prescription-only, clinician-prescribed. Subcutaneous 0.75 mg once weekly to start, usually escalated to 1.5 mg; 3.0 mg and 4.5 mg once-weekly doses are available for additional glycemic lowering. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: dulaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis).
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.
Weight loss is real but modest and includes some loss of lean mass — pair sustained weight loss with resistance training and adequate protein.
Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly pen (Trulicity)

Safety

Moderate safetyBest

Drug Interactions:

Penicillamine and other copper-chelating therapy (severe)
Other zinc-containing supplements or lozenges (moderate)
Copper supplements (moderate)

and 3 more not shown

Side Effects:

Nausea and stomach upsetZinc-induced copper deficiency, with anaemia and neutropeniaYellowing of the skin (carotenodermia)

Contraindications:

The ORIGINAL AREDS formula (containing beta-carotene) in anyone who currently smokes or has ever smoked — beta-carotene increased lung cancer incidence in ATBC (+18%) and CARET (RR 1.28), and doubled 10-year lung cancer odds in AREDS2 itself (OR 1.82)
Concurrent use with other beta-carotene or high-dose vitamin A supplements in smokers and former smokers

Limited safety

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrheaGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

What you'll notice

🐢 Slows progression of intermediate AMD to advanced AMDpositive

Years — average follow-up was 6.3 years

🔤 Less moderate visual acuity losspositive

Years

🚭 Removes the beta-carotene lung cancer riskpositive

Long-term

🔬 Geographic atrophy evidencetrade-off

Years

🩸 Improved glycemic controlpositive

Weeks to months

❤️ Reduced cardiovascular eventspositive

Months to years

⚖️ Modest weight losspositive

Months

🤢 GI adverse effects (very common)trade-off

Especially during initiation/escalation

Key studies

Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

JAMA (2013) · Rct · n=4203

Primary analysis was NULL: lutein/zeaxanthin HR 0.90 (98.7% CI 0.76-1.07, P=.12); DHA+EPA HR 0.97 (0.82-1.16, P=.70); both together HR 0.89 (0.75-1.06, P=.10)

A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8.

Arch Ophthalmol (2001) · Rct · n=3640

Antioxidants plus zinc vs placebo for advanced AMD: OR 0.72 (99% CI 0.52-0.98). Zinc alone OR 0.75 (0.55-1.03); antioxidants alone OR 0.80 (0.59-1.09) — neither significant on its own

Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.

JAMA Ophthalmol (2022) · Cohort · n=3882

10-year lung cancer odds ratio: 1.82 (95% CI 1.06-3.12, P=.02) for beta-carotene assignment vs 1.15 (0.79-1.66, P=.46) for lutein/zeaxanthin

All AREDS2 Formula studies

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Lancet (2019) · Rct · n=9901

Multicentre, double-blind, placebo-controlled cardiovascular-outcomes RCT: 9,901 patients aged ≥50 with type 2 diabetes, randomized to subcutaneous dulaglutide 1.5 mg/week or placebo at 371 sites in 24 countries

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Lancet Diabetes Endocrinol (2019) · Meta analysis

Meta-analysis of seven GLP-1 receptor agonist cardiovascular-outcomes trials (ELIXA, LEADER, SUSTAIN-6, EXSCEL, Harmony Outcomes, REWIND, PIONEER 6); 56,004 participants

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Lancet (2019) · Rct · n=9901

Pre-specified exploratory analysis of the REWIND trial (9,901 participants) examining the renal component of the composite microvascular outcome

All Dulaglutide studies

Frequently asked questions

Is AREDS2 Formula better than Dulaglutide?

Both AREDS2 Formula and Dulaglutide are closely matched — the best choice depends on your specific health goals.

Can I take AREDS2 Formula and Dulaglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

AREDS2 Formula vs L. rhamnosus GG AREDS2 Formula vs Ceramides AREDS2 Formula vs L. casei Shirota AREDS2 Formula vs L. plantarum 299v Dulaglutide vs Semaglutide Dulaglutide vs Tirzepatide

Still deciding between AREDS2 Formula and Dulaglutide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick AREDS2 Formula details Dulaglutide details

Warnings

Do not use the original beta-carotene AREDS formula if you smoke or have ever smoked — this is the single most safety-relevant fact about the product

Zinc and genitourinary problems: in the original AREDS trial, zinc was associated with a higher rate of genitourinary problems in MEN — the majority of the population taking this formula. AREDS2 found no difference between its high- and low-dose zinc groups. Gastrointestinal symptoms were the main reported adverse effect overall.

This formula does NOT prevent age-related macular degeneration in people who do not have it; Cochrane rates that as high-certainty for the individual antioxidants it tested — this formula was never trialled for prevention

It does not restore lost vision — every measured outcome was slower progression, never recovery

The evidence applies to intermediate AMD, or advanced AMD in one eye. People with only small drusen had a 1.3% five-year progression risk and gained nothing

80 mg of zinc is above established upper intake levels; the 2 mg of copper is there to prevent zinc-induced copper deficiency and must not be omitted

Adding omega-3 is not evidence-based — DHA+EPA was tested in AREDS2 and was null at both 5 and 10 years

Adding lutein/zeaxanthin did not, in the primary analysis, improve on the original formula; its established value is as a safe replacement for beta-carotene

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: dulaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis).

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are very common, especially during dose escalation.

Weight loss is real but modest and includes some loss of lean mass — pair sustained weight loss with resistance training and adequate protein.

Avoid COMPOUNDED / grey-market GLP-1 products: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Frequently asked questions

Is AREDS2 Formula better than Dulaglutide?

Both AREDS2 Formula and Dulaglutide are closely matched — the best choice depends on your specific health goals.

Can I take AREDS2 Formula and Dulaglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.